Cancer BiologybioRxiv
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
C. Eggermont, P. Giron, M. Noeparast…·J. De Greve
This study identifies STYK1 as a target that enhances the effects of EGFR inhibition in NSCLC cells, suggesting co-targeting EGFR and STYK1 may improve treatment outcomes.
DOI 10.1038/s41419-022-04994-4